Authorized Generic of Cubicin Launched
September 14, 2016 – Teva announced the launch of an authorized generic of Merck’s Cubicin® (daptomycin for injection), 500mg vials. Cubicin is indicated to treat adults with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of certain Gram-positive bacteria. Cubicin is also indicated to treat adults with Staphylococcus aureus bloodstream infections. A-rated generics to Cubicin are expected to launch in the near future.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.